Objectives: Better understanding of the dynamics of HIV reservoirs under ART is a critical step to achieve a functional HIV cure. Our objective was to assess the genetic diversity of archived HIV-1 DNA over 48 weeks in blood cells of individuals starting treatment with a dolutegravir-based regimen.
Introduction
HIV reservoirs are rapidly established following infection 1 and despite being partly reduced early in treatment, they can persist in the form of integrated proviral DNA for decades even when ART is used to prevent active replication. 2, 3 To date, neither current ART strategies nor ongoing 'shock and kill' studies have yet succeeded to significantly reduce HIV reservoirs to undetectable levels. [4] [5] [6] Accordingly, HIV reservoirs are quantitatively stable for lengthy periods of time, effectively preventing viral eradication. [7] [8] [9] The existence of genetic variability within those reservoirs and the contribution of residual replication to their active maintenance during ART both remain controversial. [10] [11] [12] [13] [14] [15] Recent studies have suggested that, in some patients, the viral reservoir is genetically stable and can be maintained by clonal expansion of latently infected cells. 16, 17 Others have argued for the existence of cryptic tissue-bound persistent replication under ART. 14 Dolutegravir was the first second-generation integrase strand transfer inhibitor (INSTI) to be approved for clinical use. 18 In part because of its high genetic barrier, dolutegravir is thought to be able to reduce HIV reservoirs. [19] [20] [21] In contrast, ART intensification with or when switched to the first-generation INSTI raltegravir had no significant effect on viral reservoirs. [22] [23] [24] Whether this would also hold true if dolutegravir was used for treatment intensification remains unstudied. To date, no data to our knowledge is yet available about the effect (if any) of dolutegravir on the levels and genetic diversity of the HIV reservoirs. The specific effect of INSTIs in blocking the HIV integration process, combined with the high genetic barrier of dolutegravir might influence the maintenance of the HIV reservoir since persistent replication under ART is involved in this process. 19 We hypothesize that studying the HIV diversity of archived quasispecies in individuals starting a dolutegravir-based regimen (DBR) would be an interesting model for understanding both the dynamics of the HIV-1 reservoirs and the mechanisms of HIV persistence under ART. 25 Thus our objective was to prospectively assess the dynamics of blood-archived HIV-DNA quasispecies over 48 weeks in individuals starting successful DBR at different clinical and therapeutic stages of HIV infection using an ultra-deep sequencing technique.
Methods

Study population and study design
This is a substudy of a multicentre prospective longitudinal study including HIV-1-infected adults starting a DBR termed DRONE (impact of a Dolutegravirbased regimen on Reservoirs Of treatment-Naive and -Experienced individuals, Clinicaltrials.gov: NCT02557997). Participants from four groups were enrolled: treatment-naive individuals who initiated treatment with a DBR during acute (e.g. less than 6 weeks post-infection) infection (AI) or chronic infection (CI), and treatment-experienced individuals who started a DBR while in virological success (VS; e.g. HIV-1 RNA ,50 copies/mL) or in the aftermath of virological failure (VF; e.g. HIV-1 RNA .50 copies/mL).
Eighty PBMC samples were collected from 20 participants (5 in each group) at baseline and week 4 (W4), week 24 (W24) and week 48 (W48) of successful DBR ( Figure S1 , available as Supplementary data at JAC Online).
Ethics statement
All participants gave written informed consent. The study was reviewed and approved by both Independent Protection Committee East 4 (NCT02557997) and the French Safety Drug Agency (ANSM).
Total HIV-1 DNA extraction and quantitation
Total cell-associated DNA was extracted from 1 million PBMCs in duplicate using the automated QIAxtractor system (QIAGEN, Courtabeouf, France), with a final elution volume of 100 lL. Total HIV-1 DNA was quantified by long terminal repeat (LTR) real-time PCR assay with the Generic HIV DNA CELL assay (Biocentric, Bandol, France) as described previously. 26 
Amplicon generation
Three bulk PCR amplicons of approximately 400 bp encompassing the whole integrase (two amplicons: Int1 4359-4743 and Int2 4743-5102 positions on HIV-1 HXB2) and the V3 loop (one amplicon: 7026-7360 positions on HIV-1 HXB2) were generated from 200 000 PBMCs per PCR (Table S1 ). Amplification of each amplicon was individually performed with unique 454 multiplex identification tags (MID) in duplicate and PCR products were then mixed for the sequencing step. First round and nested PCR were carried out with Phusion High Fidelity PCR Master Mix with HF Buffer (Thermo Scientific, Vilnius, Lithuania).
Ultra-deep sequencing
Each amplicon was purified with Agencourt AMPure XP magnetic beads (Beckman Coulter, Krefeld, Germany). Amplicons were analysed by Agilent DNA 1000 chips on Bioanalyser (Agilent Technologies, Santa Clara, CA, USA) to verify their quality and purity. The purified amplicons were quantitated with a fluorescence assay Quant-iT PicoGreen (Invitrogen, Eugene, OR, USA) according to the manufacturer's instructions. Purified amplicons were pooled in equimolar amounts. Clonal amplification on beads (emulsion PCR), bead isolation (breaking) and sequencing on a GS Junior (Roche/454, Meylan, France) were all performed according to the manufacturer's protocol. For each participant, the four samples from each timepoint and the three amplicons were deep-sequenced in the same pyrosequencing run.
Sequence analysis
Sequence reads were analysed with the GS Amplicon Variant Analyzer (AVA) software (Roche), which assigns each read to the proper amplicon and individual sample using 454 MID. This software also aligns individual sequence reads with the HIV WT HXB2 sequence. Notably, 454 pyrosequencing has known homopolymer issues. 27 To correct for homopolymer issues, first an in-house R-script was used to generate one homopolymercorrected consensus sequence per sample from the post-AVA aligned files. In this approach, 'consensus sequence' was defined as the most frequently observed nucleotide at each base position ('A', 'T', 'C', 'G' or '-'). This was followed by the removal of all gap characters in the final consensus sequences. The assumption is that homopolymer errors at a single position would not constitute the most frequently observed base, therefore by removing gap characters, homopolymer errors would not be carried over into the consensus sequence. Next, another in-house R-script was used to correct homopolymer issues in each small read. This script first aligned each raw small read to the sample-specific homopolymer-corrected consensus sequence. Then, for each base position: (i) if the small read indicated '-', but the sample-specific consensus sequence was A, C, T or G, our software would replace the base in the small read with 'N'; and (ii) if the read indicated A, C, T or G, but the sample-specific consensus sequence was '-', this '-' character would be removed from the small read. These two steps would correct for any (i) deletions and (ii) insertions that are likely artefacts resulting from the homopolymer issue. A random sample (subject ID#1, baseline, V3 loop, 3105 small reads) was used to compare results derived from our in-house scripts against a published homopolymer correction algorithm RC454. 28 Absolute sequence identities derived from the two algorithms were 97% concordant. In the majority of discordance cases, our in-house script was over-conservative, calling N instead of taking a base call from the consensus sequence. We used a cut-off of 20 reads to consider variants.
To further validate this overall approach, four PBMC samples (one random sample per subject group) were subjected to re-sequencing in separate 454 runs to assess the reproducibility of the results. Samples later identified with integrase resistance mutations by ultra-deep sequencing consensus sequence were re-extracted and re-tested by Sanger sequencing to confirm the existence of the resistance mutations ( Figure S2 ).
Phylogenetic trees were generated using the corrected consensus sequence and Clustal X neighbour-joining tree.
INSTI resistance mutations were identified using the Stanford drug resistance mutation list (updated 2017; http://hivdb.stanford.edu). Resistant variant sequences were tested for APOBEC-induced hypermutation on Hypermut (https://www.hiv.lanl.gov/content/sequence/HYPERMUT/ hypermut.html). 29 The tropism of each variant was inferred from the V3 amino acid sequence by geno2pheno available at www.geno2pheno.org. Viral quasispecies diversity was defined by Shannon entropy. 30 This measure was calculated as -[R p i .log 2 (p i )]/log 2 (N) where p i is the relative frequency of each variant i (i " 1;. . .; n, where n is the number of variants per sample) and N is the total number of sequences analysed per sample. Entropy results can vary from 0 (single variant) to 1 (each sequence represents a single variant). We used a Bayesian approach to compare genetic Gantner et al.
variability changes over follow-up assuming that genetic diversity follows a normal distribution N(l, r 2 ). Posterior distribution parameter estimates were derived using the JAGS program within the rjags package in R version 3.1.1 and were generated using Markov chain Monte Carlo computation and uninformative prior probabilities: the coefficients on l were N(0, 0.01) and on 1/r 2 were C(0.05, 0.05). 31 Comparisons between two timepoints are expressed as the probability of observing a difference in Shannon entropy greater than 0.025, which was found to be a virologically relevant threshold. 30 
Results
Population study
This report analyses 20 participants positively responding to DBR (HIV-1 RNA ,40 copies/mL) as of week 12 of DBR (Table 1 ). All individuals sustained virological control during follow-up. Associated backbones were abacavir/lamivudine (55%), tenofovir disoproxil fumarate/emtricitabine (40%) and rilpivirine (5%). Participants were primarily male (75%), with a median age of 44 years. Sixty-five percent were men who have sex with men and 90% of individuals harboured HIV-1 subtype B. Of note, individuals in the AI group were Fiebig stage V or less and individuals in the VS group underwent a median of 10 years (range, 8-11) of suppressive ART.
HIV-DNA and ultra-deep sequencing
A total of 80 PBMC samples (baseline, W4, W24 and W48) were analysed for cell-associated HIV-DNA (Table 2) , which ranged from 81 to 46 189 copies of HIV-DNA/million PBMCs. Mean decreases in amounts of cell-associated HIV-DNA between baseline and W48 were #1.30, #0.56, #0.10 and #0.54 log 10 copies/million PBMCs for the AI, CI, VS and VF groups, respectively. All sequences were successfully amplified from the 80 PBMC samples and yielded a median of 2122, 2801 and 2479 reads per Int1, Int2 and V3 amplicon, respectively.
Genetic diversity
Assuming that the 454 homopolymer produces the same Shannon entropy background noise across groups we calculated the genetic diversity for each amplicon (integrase in two parts and V3 loop) by individual at each timepoint (baseline, W4, W24 and W48) according to the inclusion group (Figure 1 ). Results were similar for the three amplicons; we will take the V3 loop as an example. Mean genetic diversity in HIV-DNA was of 0.041 at baseline in individuals starting a DBR in the AI group. In this group, genetic diversity remained stable through follow-up (0.018 at W48). Indeed, almost only one major variant was detected at each timepoint in the blood reservoir in this population. In the other groups Dolutegravir reshapes diversity of HIV reservoirs JAC (CI, VS and VF), a high level of genetic diversity at baseline was observed (0.058, 0.078 and 0.148, respectively). The start of DBR in these individuals was associated with a transient decrease in the genetic diversity of either pol or env sequences at W4 (0.008, 0.018 and 0.024, respectively). At this timepoint, only one major variant was detected in all individuals in the blood reservoir. There was a 92% probability of observing a diversity drop-off greater than 0.025 between baseline and W4. In these groups, HIV-1 proviral genetic diversity increased to levels similar to baseline from W24 to W48 (0.042, 0.074 and 0.115 at W48, respectively). There was an 84% probability of observing a re-increase in diversity greater than 0.025 between W4 and W48. For each amplicon (Int1, Int2 and V3), we constructed phylogenetic trees of HIV-DNA consensus sequences by individual and by date (Figure 2 ). We found that for subjects treated during AI, HIV-DNA consensus sequences intermingled between timepoints. On the contrary, individuals from the CI, VS and VF groups harboured HIV-DNA sequences that differed from one timepoint to another.
Drug resistance amino acid substitutions
Among 20 participants, we detected minor resistance-associated mutations in the proviral DNA from five individuals (25%; Table 2 ).
Remarkably, the R263K substitution was transiently detected in one individual (subject ID#9) from the CI group at W4 as the major variant (84% R263K variants and 16% baseline variants). The dolutegravir-specific R263K substitution was confirmed through Sanger sequencing ( Figure S2 ). The R263K variant was genetically distinct from the baseline variant by seven nucleotide changes (five were G-to-A mutations), but harboured no stop codons and was not considered hypermutated (P " 0.1). Proviruses from three individuals from the VS group harboured various substitutions in the N-terminal region (subject ID#15: T50I at W48; subject ID#12: M50I at W4, W24 and W48; subject ID#14: I50T at W4 and W48, and I50M at W24) and the N230S substitution was observed in one individual from the AI group (Fiebig V) at W4 and W48 (subject ID#2). In subject ID#12, M50I was associated with the A124T substitution. Importantly, no major resistance-associated substitutions such as Q148, Y143 or N155 were detected.
Discussion
Understanding the dynamics and persistence of HIV reservoirs under ART is important for evaluating the efficacy of future interventions aimed at curing HIV infection. In this study, we examined the genetic diversity of HIV-1 DNA isolated from the PBMCs of individuals starting a DBR at different clinical and therapeutic stages of 
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HIV infection by ultra-deep sequencing. We demonstrated for the first time a specific pattern of genetic diversity while changing or initiating successful DBR: (i) genetic diversity remains low in individuals starting a DBR during AI; (ii) a dramatic decrease in viral diversity at W4 of DBR occurs in other individuals; (iii) a re-increase in viral diversity over time occurs in all individuals except those initiating DBR during the acute phase; and (iv) a selection of amino acid substitutions specifically associated with resistance to INSTI can occur during DBR. Our data suggest that switching from other drug regimens to a DBR, even after long periods of viral suppression, can influence the genetic makeup of the HIV-1 reservoir. Focusing on the five individuals who initiated a DBR during AI, we found that HIV-1 reservoirs were composed almost uniquely of only one viral variant that filled the PBMC DNA reservoir and that this single variant persisted under ART. We can hypothesize that blood cells may harbour the single transmitted founder clone, 32 filling all the HIV reservoirs at baseline and on follow-up. In AI, it was shown that a single viral cluster circulated throughout blood and other reservoirs. 33, 34 The persistence of a stable unique variant during DBR is indicative of the absence of low-level viral replication in this population of patients. Whether longer periods of time will slowly increase the genetic diversity of the reservoirs in these individuals is a critical question. Based on our results that all individuals successfully treated for 10 years (VS group) did possess a highly diversified reservoir, we hypothesize that this will also become true for the AI patients. However, individuals treated during primary infection achieve very low levels of HIV reservoirs while on ART and thus may have a lower risk of residual replication. 35 Alternatively, our results may be explained by the immune pressure of cytotoxic T lymphocyte (CTL) response on the genetic diversity of the viral reservoirs in acutely infected patients. Indeed, participants of this group initiated therapy at Fiebig stages II (n " 1), IV (n " 1) or V (n " 3) and the acquisition of CTL-escape genetic mutations occurs mostly at stage V. 36 , 37 We have not looked for such escape mutations in our study and thus effects of CTL pressure on HIV-1 genetic diversity have been overlooked. In contrast with acutely infected individuals, participants from all the other groups, i.e. those initiating DBR during CI or in the aftermath of VF or those who are virologically controlled on ART switching to DBR, all showed a profound shift in the genetic diversity of the HIV-1 reservoirs. For these individuals, our results show: (i) a high level of viral diversity at baseline and (ii) an early genetic homogenization of the viral reservoirs after 4 weeks of DBR initiation/switch, followed by (iii) a slow increase in genetic diversity that eventually reached levels similar to that at baseline, after one year of treatment. This last observation could be owing to either low levels of persistent residual replication under ART 38 or cell trafficking from tissues to the blood compartments. 39 Indeed, the HIV cellular reservoir shows high diversity in terms of cell subtypes, anatomical location, half-life and cell homeostasis. In these different kinds of reservoirs, both selective immune pressure and drug pressure might be variable. 17, [40] [41] [42] [43] In this regard, the detection of variants bearing drug-specific resistance-associated mutations may be significant.
Although drug resistance is extremely rare against dolutegravir, treatment failure with DBR has been commonly associated with the emergence of the R263K integrase substitution. 44, 45 We report here three important observations. First, major variants bearing the R263K substitution did emerge and were archived within the DNA of one individual under DBR. Second, detecting R263K in the proviral DNA was not associated with VF. Third, multiple changes at integrase position 50 were also detected over time in the viral reservoirs of individuals using DBR. In all cases, these changes at position 50 were conserved over time. We previously showed the emergence of the R263K and M50I combination of substitutions in tissue culture selection experiments with dolutegravir. 44 Position 50 is naturally polymorphic whereas R263K is a rare polymorphic resistance-associated substitution. Either of the R263K or M50I substitutions confer similar low levels (2-fold) of resistance to Gantner et al.
dolutegravir in cell culture. 46 In the absence of active replication, integrase substitutions at position 50 cannot provide any evolutionary advantage to the virus under dolutegravir pressure, thus the conservation of substitutions at position 50 over time is more likely due to persistent replication under treatment than to redistribution of latently infected cells. The absence of maintenance of R263K could be due to specific fitness costs imparted by this substitution to HIV-1, in agreement with previous reports. 47, 48 This again can only be true if HIV-1 undergoes cryptic replicative cycles under DBR, in all likelihood in solid organs or lymph nodes. This in turn may have to do with issues of drug penetration within various organs. 43, 49 Why individuals who initiated DBR after VF were the only group not to have emerging variants with drug resistance-associated mutations remains unknown but might also have to do with issues of viral fitness. Alternatively, this could simply be due to the small number of participants in our study. Of note, both R263K and M50I have been recently associated with low levels of resistance to another INSTI termed bictegravir. 50 Given our results, we suggest an evolutionary pathway for each of our four groups of individuals in Figure 3 . Our model is based on the hypothesis that cell trafficking and/or residual replication, associated with a high level of compartmentalization of HIV reservoirs, are the driving force of genetic diversification in blood-archived HIV quasispecies. On the one hand, individuals treated during AI are at lower risk of generating viral diversity. On the other hand, individuals treated during CI and cases of VF or VS are at higher risk of genetic diversification. In the latter case, residual replication can produce viral diversity while on ART. This suggests that clonal expansion produces no changes in the genetic diversity of viral reservoirs (i.e. AI group), [11] [12] [13] [14] [15] whereas residual replication on ART, when it exists, affects HIV-DNA genetic diversity (i.e. CI, VS and VF groups).
14-16 These mechanisms probably co-exist, but replicative-and infectivecompetent variants seem to preferentially derive from clonally expanded cells. 16 Our study has several limitations, including the small number of participants and technical issues. We tried to avoid artefact results due to 454 pyrosequencing errors with some controls (duplicate sequencing, Sanger confirmation, sequences cleaning). We cannot exclude a sampling effect for the PBMCs analysed which may not summarize all archived quasispecies, though; by assuming that 454 sequencing errors lead to the same level of background noise in Shannon entropy across samples and across study arms, our results are clear with a marked inflection point in genetic diversity in almost all participants. Moreover, our well-characterized cohort Initiating a DBR can significantly reduce both HIV RNA and DNA. Concurrently, we observed a dramatic transient reduction of the genetic diversity on both pol and env genes from archived HIV quasispecies at W4 of treatment. Up to 48 weeks of treatment in our longitudinal follow-up and despite virological suppression in plasma and HIV-DNA level reduction in PBMCs, we observed a slow recovery of the genetic diversity of the reservoirs. Also some viral variants harbouring dolutegravir resistance-associated mutations, including the R263K substitution, were detected in some individuals. These findings show that the HIV reservoir genetic diversity is reshaped following the initiation of a DBR, suggesting the presence of residual replication and/or cell trafficking between the blood compartment and solid tissues.
